These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 29464437)

  • 21. Adverse Reactions to Biologics in Psoriasis.
    Lockwood SJ; Prens LM; Kimball AB
    Curr Probl Dermatol; 2018; 53():1-14. PubMed ID: 29131033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease.
    Mocci G; Marzo M; Papa A; Armuzzi A; Guidi L
    J Crohns Colitis; 2013 Nov; 7(10):769-79. PubMed ID: 23453887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of biologics in the treatment of moderate-to-severe plaque psoriasis.
    Puig L
    G Ital Dermatol Venereol; 2017 Feb; 152(1):28-35. PubMed ID: 27627100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paradoxical eczema in patients with psoriasis receiving biologics: a case series.
    Al-Janabi A; Foulkes AC; Griffiths CEM; Warren RB
    Clin Exp Dermatol; 2022 Jun; 47(6):1174-1178. PubMed ID: 35150003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders.
    Balato A; Scala E; Balato N; Caiazzo G; Di Caprio R; Monfrecola G; Raimondo A; Lembo S; Ayala F
    Expert Opin Biol Ther; 2017 Nov; 17(11):1363-1374. PubMed ID: 28791896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy.
    Ozguler Y; Hatemi G; Ugurlu S; Seyahi E; Melikoglu M; Borekci S; Atahan E; Ongen G; Hamuryudan V
    Rheumatol Int; 2016 Dec; 36(12):1719-1725. PubMed ID: 27699578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cutaneous adverse effects of the immune checkpoint inhibitors.
    Collins LK; Chapman MS; Carter JB; Samie FH
    Curr Probl Cancer; 2017; 41(2):125-128. PubMed ID: 28190531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse Reactions to Biologic Therapy.
    Patel SV; Khan DA
    Immunol Allergy Clin North Am; 2017 May; 37(2):397-412. PubMed ID: 28366484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis.
    Frieder J; Kivelevitch D; Fiore CT; Saad S; Menter A
    Expert Rev Clin Immunol; 2018 Jan; 14(1):1-19. PubMed ID: 29110556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-α inhibitor therapy. A study of 16 biopsies.
    Laga AC; Vleugels RA; Qureshi AA; Velazquez EF
    Am J Dermatopathol; 2010 Aug; 32(6):568-73. PubMed ID: 20520526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review and Practical Guidance on Managing Fungal Infections in Patients With Psoriasis Receiving Anti-IL-17 Therapies.
    Yeung J; Bunce PE; Lynde CW; Turchin I; Vender RB
    J Cutan Med Surg; 2022; 26(1_suppl):3S-23S. PubMed ID: 35819172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.
    Mok CC; Chan KY; Lee KL; Tam LS; Lee KW;
    Int J Rheum Dis; 2014 Dec; 17 Suppl 3():1-8. PubMed ID: 24382315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis.
    Bissonnette R; Kerdel F; Naldi L; Papp K; Galindo C; Langholff W; Tang KL; Szapary P; Fakharzadeh S; Srivastava B; Goyal K; Gottlieb AB
    J Drugs Dermatol; 2017 Oct; 16(10):1002-1013. PubMed ID: 29036254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cutaneous adverse effects of biologic medications.
    Pasadyn SR; Knabel D; Fernandez AP; Warren CB
    Cleve Clin J Med; 2020 May; 87(5):288-299. PubMed ID: 32357984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biological therapies in the treatment of cutaneous lupus erythematosus.
    Presto JK; Hejazi EZ; Werth VP
    Lupus; 2017 Feb; 26(2):115-118. PubMed ID: 27687023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
    Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS
    JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging landscape in psoriasis management: From topical application to targeting biomolecules.
    Rapalli VK; Singhvi G; Dubey SK; Gupta G; Chellappan DK; Dua K
    Biomed Pharmacother; 2018 Oct; 106():707-713. PubMed ID: 29990862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor- α Inhibitors.
    Campanati A; Molinelli E; Brisigotti V; Offidani A
    Curr Pharm Biotechnol; 2017; 18(12):945-963. PubMed ID: 29424306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biologics for pityriasis rubra pilaris treatment: A review of the literature.
    Napolitano M; Abeni D; Didona B
    J Am Acad Dermatol; 2018 Aug; 79(2):353-359.e11. PubMed ID: 29609014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.